Vivek Rudrapatna, MD
Internal Medicine · Salinas, CANPI 1740477074
Payments from drug & device makers
What this record shows
41 manufacturers reported payments, led by Ironwood Pharmaceuticals, Inc at 45.7% of the total. Reporting peaked in 2024 at $7,945 and has fallen 86.8% since, to $1,052 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $33.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironwood Pharmaceuticals, Inc$7K
- AbbVie$1K
- Amgen$820
- Novo Nordisk$757
- Pfizer$667
- GSK$593
- plus $4K from 35 others
Across 5 payments — averaging $68,855 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$344K
What the payments were for
- Consulting fees$6,50046%
- Food & beverage$7,72354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$14,223 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 238 | $227,150 |
| EliquisApixaban | 191 | $121,354 |
| TrulicityDulaglutide | 66 | $96,106 |
| TradjentaLinagliptin | 101 | $64,170 |
| OzempicSemaglutide | 44 | $45,770 |
| FarxigaDapagliflozin Propanediol | 33 | $27,929 |
| JanuviaSitagliptin Phosphate | 22 | $27,757 |
| RybelsusSemaglutide | 15 | $24,024 |
| LinzessLinaclotide | 14 | $22,156 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $17,359 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $16,608 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $13,371 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $12,156 |
| XareltoRivaroxaban | 19 | $12,076 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $10,970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $38 | $291,320339 claims |
| PfizerEliquis | $667 | $121,354191 claims |
| Lilly USA, LLCTrulicity | $549 | $96,10666 claims |
| Novo NordiskOzempic, Rybelsus | $757 | $69,79459 claims |
| MerckJanuvia, Janumet | $130 | $44,36541 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $593 | $41,44977 claims |
| AstraZenecaFarxiga | $251 | $27,92933 claims |
| AbbVieLinzess | $1,279 | $22,15614 claims |
| Johnson & JohnsonXarelto | $147 | $12,07619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Salinas
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.